Is it time to bail out of easyJet plc and buy GlaxoSmithKline plc instead?

A warning shot from easyJet plc (LON: EZJ) diverts attention to stable enterprises such as GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The main takeaway I get from today’s half-year report from airline operator easyJet (LSE: EZJ) is that net cash from operations is down 40% compared to the equivalent period last year and the firm made an earnings-per-share loss of 5.1p, which compares to a profit of 1.3p per share last year.

No wonder, then, at 1,500p, the shares are down around 14% since the beginning of 2016. Whichever way we dress it up, this isn’t a good result for easyJet and the firm’s shareholders.

Precarious profits

The outcome here demonstrates what a precarious juggling act it is to keep an airline profitable and growing. During the period, easyJet faced pressure on its business from justifiably skittish customers due to travel strikes and terror attacks on European capitals.

That’s the thing with an airline: we never know when a natural disaster such as an Icelandic volcano or man-made disasters such as war, conflict, strike, terrorism or commodity speculation will shoot down the firm’s profitability. But it gets worse than that. Airlines are also at the mercy of macroeconomic events making airline businesses and their shares among the most cyclical on the stock market.

That cyclicality has implications about how the market is likely to value businesses such as easyJet. The more mature a macro-cycle becomes, the lower I would expect easyJet’s valuation to be as the market tries to anticipate the next cyclical down-leg by discounting high earnings in the boom times.

Consumer demand strong

Right now, easyJet trades on a forward price-to-earnings (P/E) ratio of nine for the year to September 2017 and sports a twice-covered 4.7% dividend yield. I wouldn’t expect a higher valuation than that, so any further share price progress probably needs to come from business growth rather than from a valuation rerating.

Carolyn McCall, easyJet’s chief executive says: easyJet has delivered a robust financial performance during the half year despite the well-publicised external events. Underlying consumer demand has been strong with UK beach traffic providing a healthy start to the half and easyJet’s biggest-ever ski season helping to deliver increased passenger numbers and higher revenue during H1.

Okay. But it’s precisely when things are going at their best that we should expect a cyclical top, often followed by a descent into the next cyclical bottom. Nobody knows when the top will arrive, but I’m taking these first-half losses as a warning shot and now I’m avoiding easyJet shares.

A more robust business model

Pharmaceutical giant GlaxoSmithKline (LSE: GSK) enjoys a more robust business model than easyJet’s. The stable nature of demand for medicines makes GlaxoSmithKline’s operation far less cyclical and keeps the cash taps flowing as consumers repeat purchase drugs.

Sure, the pharmaceutical industry had its challenges over patent expiry issues as once high-earning formulations lost exclusivity in the market and the firm saw a flood of generic competition erode profits. However, the company is moving on from that and hopes a new generation of blockbusters will return the firm to enduring growth.

City analysts following the firm expect earnings to grow 16% this year and 4% during 2014. At today’s 1,475p share price GlaxoSmithKline trades on a forward P/E rating of just over 16 for 2017 and yields a dividend of 5.4% covered just over once by forward earnings. That’s a fair valuation for a defensive business with reasonable forward growth prospects.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Front view of aircraft in flight.
Investing Articles

Is it game over for the BP share price rally?

The BP share price has looked like a one-way bet in recent weeks as oil and gas prices soar but…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Amid geopolitical and AI risks, here’s how I’m positioning my ISA and SIPP in 2026

Edward Sheldon explains how he's allocating capital within his investment accounts and SIPP amid the various risks to the market.

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

My game plan for the next stock market crash

Markets have been surprisingly resilient during the recent Middle East conflict but we still cannot rule out a stock market…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

1 top growth stock to consider buying after it crashed 59%

This S&P 500 growth stock has fallen off a cliff lately due to AI software fears. Our writer thinks this…

Read more »

A mature woman help a senior woman out of a car as she takes her to the shops.
Investing Articles

Here’s how a 35-year-old putting £15 a day into an ISA could end up earning £18k+ of passive income annually!

A 35-year-old with no ISA but a willingness to invest relatively small sums could one day be earning many thousands…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

With the potential to double in 10 years, this could be a dividend stock to consider buying

With a yield of 7.2%, income investors might consider buying this stock. But reinvesting the dividends could deliver even more…

Read more »

Happy couple showing relief at news
Investing Articles

How much would someone need to invest in the stock market to target a £1,250 monthly second income?

Investing in the stock market can help deliver long-term wealth. But James Beard says it can also be a way…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How much would someone need in an ISA to aim to treble the current State Pension?

Experts say the State Pension isn’t generous enough to provide a comfortable retirement. James Beard says the stock market could…

Read more »